newsfilter
← Latest News
GlobeNewswire·

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study